Treatment Landscape for Metastatic Castrate-Sensitive Prostate Cancer: A Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38025805/
With the advent of new therapeutic modalities, management of metastatic castrate-sensitive prostate cancer (mCSPC) has been in flux. From androgen-deprivation therapy to docetaxel to androgen receptor-signaling inhibitors, each agent has...
Management of metastatic castrate-sensitive prostate cancer is evolving, with new therapeutic modalities like androgen receptor-signaling inhibitors and triplet therapy emerging, although optimal first-line treatment remains unclear.
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38644146/
Darolutamide + ADT + docetaxel led to deep and durable PSA responses in patients with high- or low-volume mHSPC. Achievement of undetectable PSA (<0.2 ng/ml) was correlated with better clinical...
In the ARASENS trial, darolutamide with ADT and docetaxel significantly increased undetectable PSA rates and improved overall survival, highlighting its efficacy in metastatic hormone-sensitive prostate cancer.
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38394384/
ClinicalTrials.gov identifier NCT02200614.
Darolutamide was well tolerated in patients with nonmetastatic castration-resistant prostate cancer, showing low incidences of treatment-emergent adverse events and no new safety signals during extended treatment.
Pharmacokinetic Interactions Between Abiraterone, Apalutamide, Darolutamide or Enzalutamide and Antithrombotic Drugs: Prediction of Clinical Events and Review of Pharmacological Information - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37126188/
Numerous interactions are expected between enzalutamide or apalutamide and antithrombotics, for which management should be deployed on a case-by-case basis. PK and pharmaco-epidemiological studies could shed light on whether or...
Abiraterone, apalutamide, darolutamide, and enzalutamide exhibit varying pharmacokinetics, with apalutamide and enzalutamide posing potential drug-drug interactions with antithrombotics, necessitating case-by-case management and further research.
Prostate Cancer: Management of Biochemical Recurrence after Surgery - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38186066/
Radical prostatectomy (RP) is one of the primary treatment options for localised prostate cancer (PCa). Despite its curative intent, 1/3 of patients will experience biochemical recurrence (BCR) during follow-up. Experts...
Radical prostatectomy for localized prostate cancer may lead to biochemical recurrence in one-third of patients. This review evaluates controversial treatment options and future directions for managing recurrence effectively.